Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
01 July 2022 | Story André Damons | Photo André Damons
Prof Motlalepula Matsabisa
Prof Motlalepula Matsabisa, from the Department of Pharmacology at the University of the Free State, explains to the delegation how some of the machinery and equipment in his laboratory work.

The World Health Organisation’s (WHO Afro) Regional Expert Advisory Committee on Traditional Medicines for COVID-19 Response (REACT), Africa Centres for Disease Control and Prevention (Africa CDC), the European and Developing Countries Clinical Trials Partnership (EDCTP), the African Union Commission (AU) joint mission to South Africa have found that the University of the Free State (UFS) has the appropriate laboratories, specialised facilities and capacity to conduct multidisciplinary research, train human resources as well as the ability to attract funding for research on traditional medicine. 

The mission concluded its visit to the country on Friday 24 June by presenting a preliminary report to the departments of Health and Higher Education and Training (DHET). Besides visiting the two national departments and the UFS, the delegation also visited the South African Health Products Regulatory Authority (SAHPRA), WHO Country Office, Pharma-Ethics, Manufacturing Industry and the Council for Scientific and Industrial Research (CSIR). They also visited the three clinical trials sites in Vereeniging, Kimberley and Gqeberha (Port Elizabeth). 

Congratulations to UFS and Department of Clinical Pharmacology for PHELA study
The delegation visited the UFS (on Friday 17 June) as it is one of two institutions on the continent conducting multicentered clinical trials on traditional African medicine – PHELA – to be tested in a Phase II clinical trial on COVID-19 patients.

Prof Ossy MJ Kasilo, regional advisor for traditional medicine at the WHO regional office for Africa, who led the mission, congratulated the UFS and the Department of Clinical Pharmacology for putting together the study for PHELA.
According to her, South Africa is one of just two countries they visited conducting multicentered clinical trials on traditional African medicine for COVID-19. “This study is very important to us and on behalf of the WHO Africa, AFRICA CDC, EDCTP and the AU Commission, we would like to congratulate you on this study,” said Prof Kasilo. 
Presenting the preliminary report to the Departments of Health and DHET, Prof Kasilo said they found that the UFS has the appropriate laboratories, research equipment, specialised facilities and capacity to conduct multidisciplinary research, for human capital development, as well as the ability to attract funding. 

“The university also has strong institutional and government support, the existence of an institutional ethics committee and a strong relationship with the industry. There is also strong evidence of collaboration between departments at the UFS; these include Pharmacology, Chemistry, Microbiology and Virology as well as the external research collaboration that includes the Council for Scientific and Industrial Research (CSIR), University of Pretoria, Agricultural research council (UP) and others. 

“The UFS has strong involvement and relationships with communities and the Krwakrwa outreach in the Eastern Cape is an example of university-community partnership. The university together with the Krwakrwa community also has the facility for processing raw materials for herbal medicines, land for pilot medicinal plant cultivation and for later expansion. There are greenhouses for plant nurseries and this project is close to the source of raw materials for traditional medicines being scientifically researched and developed. The community has been trained in a number of skills relevant to them, such as good agricultural cultivation practice (GACP) project management, plant raw material quality processing and capacity building for the Project Team in relevant soft skills relating to management of processing raw materials and facilities,” said Prof Kasilo. 

The objectives of the mission
During their visit to the UFS, Prof Kasilo said with the COVID-19 pandemic a number of African countries had proposed some traditional medicine as therapeutics for COVID-19 treatment. However, these were not backed up by scientific evidence for the safety, efficacy and quality. Therefore the WHO, in collaboration with Africa CDC, African Union Commission and the EDCTP put together protocols for conducting clinical trials on traditional medicine-based therapeutics. 

“The objective of the mission is to review progress the country is making in developing traditional medicine-based therapeutics, in this particular case, PHELA. To identify areas for strengthening country capacity with the view to developing a plan of action with WHO technical support and to monitor the level of implementation of the WHO recommendations regarding the conduct of clinical trials, specifically good clinical practice,” said Prof Kasilo. 

Overview of the UFS 
Prof Motlalepula Matsabisa , who is also the chairperson of REACT, said the mission is here to ascertain the best practices, to identify the possible skills, research facilities and to identify the strength and weaknesses as well as the experts in the country who can be tapped into to give technical support on the continent. “We are not only talking to people, but we are also looking at facilities that could be utilised in the region.”
He also gave the delegates an overview on his PHELA study.  

In her short address, Prof Corli Witthuhn, Vice-Rector: Research and Internationalisation, gave a brief overview on the UFS. According to her, 3% of the university’s 41 000 students are international students – something the UFS would like to increase. In terms of internationalisation, Prof Witthuhn concluded, the UFS has 70 international active partnerships and is proud to have published almost 6 000 research publications in the past five-year period in collaboration with its international researchers and 2 500 international universities. 

According to her, the vision of the university is to be research-led, student-centered and regionally engaged so it can have an impact regionally. “We always talk about playing a national game but with an international audience.” Prof Witthuhn said.

Representatives also toured some of the university’s world-class laboratories in the Department of Pharmacology, Department of Microbiology and Biochemistry, FARMOVS as well as the Prof Felicity Burt’s biosafety Level (BSL) 3 virology laboratory where they got a glimpse into the work being done in these facilities. They also interacted with students and got to see top-of-the-range research equipment. 

 

News Archive

Inaugural lecture: Prof Robert Bragg, Dept. of Microbial, Biochemical and Food Biotechnology
2006-05-17



Attending the inaugural lecture were in front from the left Prof Robert Bragg (lecturer at the Department of Microbial, Biochemical and Food Biotechnology) and Frederick Fourie (Rector and Vice-Chancellor).  At the back from the left were Prof James du Preez (Departmental Chairperson:  Department of Microbial, Biochemical and Food Biotechnology) and Prof Herman van Schalkwyk (Dean: Faculty of Natural and Agricultural Sciences). Photo: Stephen Collett
 

A summary of an inaugural lecture delivered by Prof Robert Bragg at the University of the Free State:

CONTROL OF INFECTIOUS AVIAN DISEASES – LESSONS FOR MAN?

Prof Robert R Bragg
Department of Microbial, Biochemical and Food Biotechnology
University of the Free State

“Many of the lessons learnt in disease control in poultry will have application on human medicine,” said Prof Robert Bragg, lecturer at the University of the Free State’s (UFS) Department of Microbial, Biochemical and Food Biotechnology during his inaugural lecture.

Prof Bragg said the development of vaccines remains the main stay of disease control in humans as well as in avian species.  Disease control can not rely on vaccination alone and other disease-control options must be examined.  

“With the increasing problems of antibiotic resistance, the use of disinfection and bio security are becoming more important,” he said.

“Avian influenza (AI) is an example of a disease which can spread from birds to humans.  Hopefully this virus will not develop human to human transmission,” said Prof Bragg.

According to Prof Bragg, South Africa is not on the migration route of water birds, which are the main transmitters of AI.  “This makes South Africa one of the countries less likely to get the disease,” he said.

If the AI virus does develop human to human transmission, it could make the 1918 flu pandemic pale into insignificance.  During the 1918 flu pandemic, the virus had a mortality rate of only 3%, yet more than 50 million people died.

Although the AI virus has not developed human-to-human transmission, all human cases have been related to direct contact with infected birds. The mortality rate in humans who have contracted this virus is 67%.

“Apart from the obvious fears for the human population, this virus is a very serious poultry pathogen and can cause 100% mortality in poultry populations.  Poultry meat and egg production is the staple protein source in most countries around the world. The virus is currently devastating the poultry industry world-wide,” said Prof Bragg.

Prof Bragg’s research activities on avian diseases started off with the investigation of diseases in poultry.  “The average life cycle of a broiler chicken is 42 days.  After this short time, they are slaughtered.  As a result of the short generation time in poultry, one can observe changes in microbial populations as a result of the use of vaccines, antibiotics and disinfectants,” said Prof Bragg.   

“Much of my research effort has been directed towards the control of infectious coryza in layers, which is caused by the bacterium Avibacterium paragallinarum.  This disease is a type of sinusitis in the layer chickens and can cause a drop in egg product of up to 40%,” said Prof Bragg.

The vaccines used around the world in an attempt to control this disease are all inactivated vaccines. One of the most important points is the selection of the correct strains of the bacterium to use in the vaccine.

Prof Bragg established that in South Africa, there are four different serovars of the bacterium and one of these, the serovar C-3 strain, was believed to be unique to Southern Africa. He also recently discovered this serovar for the first time in Israel, thus indicating that this serovar might have a wider distribution than originally believed.

Vaccines used in this country did not contain this serovar.  Prof Bragg established that the long term use of vaccines not containing the local South African strain resulted in a shift in the population distribution of the pathogen.

Prof Bragg’s research activities also include disease control in parrots and pigeons.   “One of the main research projects in my group is on the disease in parrots caused by the circovirus Beak and Feather Disease virus. This virus causes serious problems in the parrot breeding industry in this country. This virus is also threatening the highly endangered and endemic Cape Parrot,” said Prof Bragg.

Prof Bragg’s research group is currently working on the development of a DNA vaccine which will assist in the control of the disease, not only in the parrot breeding industry, but also to help the highly endangered Cape Parrot in its battle for survival.

“Not all of our research efforts are directed towards infectious coryza or the Beak and Feather Disease virus.  One of my Masters students is currently investigating the cell receptors involved in the binding of Newcastle Disease virus to cancerous cells and normal cells of humans. This work will also eventually lead to a possible treatment of cancer in humans and will assist with the development of a recombinant vaccine for Newcastle disease virus,” said Prof Bragg.

We are also currently investigating an “unknown” virus which causes disease problems in poultry in the Western Cape,” said Prof Bragg.
 
“Although disinfection has been extensively used in the poultry industry, it has only been done at the pre-placement stage. In other words, disinfectants are used before the birds are placed into the house. Once the birds are placed, all use of disinfectants stops,” said Prof Bragg.

“Disinfection and bio security can be seen as the ‘Cinderella’ of disease control in poultry.  This is also true for human medicine. One just has to look at the high numbers of people who die from hospital-acquired infections to realise that disinfection is not a concept which is really clear in human health care,” said Prof Bragg.

Much research has been done in the control of diseases through vaccination and through the use of antibiotics. “These pillars of disease control are, however, starting to crumble and more effort is needed on disinfection and bio security,” said Prof Bragg.

Prof Bragg has been working in close co-operation with a chemical manufacturing company in Stellenbosch to develop a unique disinfectant which his highly effective yet not toxic to the birds.

As a result of this unique product, he has developed the continual disinfection program for use in poultry. In this program the disinfectant is used throughout the production cycle of the birds. It is also used to ensure that there is excellent pre-placement disinfection.

“The program is extensively used for the control of infectious diseases in the parrot-breeding industry in South Africa and the product has been registered in 15 countries around the world with registration in the USA in the final process,” said Prof Bragg.

“Although the problem of plasmid mediated resistance to disinfectants is starting to rear its ugly head, this has allowed for the opening of a new research field which my group will hopefully exploit in the near future,” he said.

 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept